Floatz logo

su011248

Hematopoietic and Lymphoid System Neoplasm

OHSU Knight Cancer InstitutePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Hematopoietic and Lymphoid System Neoplasm cohort.

Asset / SponsorPhaseRating
Methylene Blue
Mayo Clinic
Phase 3BB
Bendamustine
Yale University
Phase 2B
ag-120
M.D. Anderson Cancer Center
Phase 1/2CCC
Synthetic Mva-Based Sars-Cov-2 Vaccine Geo-Cm04S1
GeoVax, Inc.
Phase 2CCC
Ipilimumab
OHSU Knight Cancer Institute
Phase 1CC

View all 33 →

Same molecule, other indications

su011248 is also rated in:

Gastrointestinal Stromal TumorsDormant
BBB
Indicative ·
75 / 100
View asset →
Pancreatic Neuroendocrine TumorDormant
BB
Indicative ·
69 / 100
View asset →
Renal Cell CarcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →